Quick Answer
Coya Therapeutics, Inc. reported Total Revenue of $7.95 million for fiscal year 2025.
Coya Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $7.95M +123.6% |
$3.55M -40.8% |
$6.00M | $0.00 | — | — |
| Net Income | -$21.23M -42.6% |
-$14.88M -86.3% |
-$7.99M +34.8% |
-$12.24M -150.3% |
-$4.89M | — |
| Diluted EPS | -$1.27 -29.6% |
-$0.98 -24.1% |
-$0.79 +83.3% |
-$4.73 -150.3% |
-$1.89 | — |
| Total Assets | $49.95M +12.6% |
$44.35M +7.5% |
$41.26M +391.5% |
$8.40M +75.2% |
$4.79M | — |
| Cash and Equivalents | $46.82M +22.1% |
$38.34M +17.5% |
$32.63M +449.9% |
$5.93M +36.7% |
$4.34M | — |
| Stockholders Equity | $43.03M +8.7% |
$39.58M +11.1% |
$35.64M +524.6% |
-$8.39M -330.4% |
$3.64M -56.1% |
$8.30M |
| Operating Income | -$22.56M -30.8% |
-$17.25M -118.3% |
-$7.90M +19.5% |
-$9.81M -101.5% |
-$4.87M | — |
| Shares Outstanding | 20.93M +25.3% |
16.71M +16.0% |
14.41M +456.1% |
2.59M +0.0% |
2.59M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $3.56M | — | +2078.4% |
| Net Income | September 30, 2025 | -$2.12M | +47.4% | +65.3% |
| Diluted EPS | September 30, 2025 | -$0.13 | +50.0% | +63.9% |
| Total Assets | September 30, 2025 | $32.04M | -9.9% | -4.2% |
| Cash and Equivalents | September 30, 2025 | $28.13M | -9.4% | -5.5% |
| Stockholders Equity | September 30, 2025 | $27.28M | -14.8% | -3.6% |
| Operating Income | September 30, 2025 | -$2.43M | +45.3% | +62.1% |
| Shares Outstanding | September 30, 2025 | 16.74M | +10.0% | +0.1% |
- Coya Therapeutics, Inc. reported Total Revenue of $7.95 million for fiscal year 2025.
- Coya Therapeutics, Inc. showed an increase of +123.6% in Total Revenue compared to the prior fiscal year.
- Coya Therapeutics, Inc. reported Net Income of -$21.23 million for fiscal year 2025.
- Coya Therapeutics, Inc. showed a decrease of -42.6% in Net Income compared to the prior fiscal year.
- Coya Therapeutics, Inc. reported Diluted EPS of $1.27 per share (loss) for fiscal year 2025.
- Coya Therapeutics, Inc. showed a decrease of -29.6% in Diluted EPS compared to the prior fiscal year.
- Coya Therapeutics, Inc. reported Total Assets of $49.95 million for fiscal year 2025.
- Coya Therapeutics, Inc. showed an increase of +12.6% in Total Assets compared to the prior fiscal year.
- Coya Therapeutics, Inc. reported Cash and Equivalents of $46.82 million for fiscal year 2025.
- Coya Therapeutics, Inc. showed an increase of +22.1% in Cash and Equivalents compared to the prior fiscal year.
- Coya Therapeutics, Inc. reported Stockholders Equity of $43.03 million for fiscal year 2025.
- Coya Therapeutics, Inc. showed an increase of +8.7% in Stockholders Equity compared to the prior fiscal year.
- Coya Therapeutics, Inc. reported Operating Income of -$22.56 million for fiscal year 2025.
- Coya Therapeutics, Inc. showed a decrease of -30.8% in Operating Income compared to the prior fiscal year.
- Coya Therapeutics, Inc. reported Shares Outstanding of 20.93 million shares for fiscal year 2025.
- Coya Therapeutics, Inc. showed an increase of +25.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: